tiprankstipranks
Trending News
More News >
Mabpharm Limited (HK:2181)
:2181
Hong Kong Market
Advertisement

Mabpharm Limited (2181) AI Stock Analysis

Compare
0 Followers

Top Page

HK:2181

Mabpharm Limited

(2181)

Rating:48Neutral
Price Target:
HK$0.50
▼(-3.85% Downside)
The overall score reflects significant financial challenges, including high leverage and lack of profitability. Despite strong revenue growth, these issues overshadow the positive technical momentum. The valuation further dampens the outlook due to negative earnings.

Mabpharm Limited (2181) vs. iShares MSCI Hong Kong ETF (EWH)

Mabpharm Limited Business Overview & Revenue Model

Company DescriptionMabpharm Limited (2181) is a biopharmaceutical company focused on the research, development, and commercialization of innovative drugs primarily for the treatment of cancer and autoimmune diseases. The company operates in the pharmaceutical and healthcare sectors and is dedicated to improving patient outcomes through its advanced biologic therapies.
How the Company Makes MoneyMabpharm Limited generates revenue primarily through the sale of its proprietary biopharmaceutical products. The company invests heavily in research and development to create novel therapeutics that address unmet medical needs in oncology and immunology. Revenue streams include direct sales of approved drugs, licensing agreements, and strategic partnerships with other pharmaceutical companies for co-development and distribution. Additionally, Mabpharm may receive milestone payments and royalties from collaborations and licensing deals, further contributing to its earnings.

Mabpharm Limited Financial Statement Overview

Summary
Mabpharm Limited has shown significant revenue growth but continues to face profitability and financial stability challenges. High leverage, negative cash flows, and consistent losses indicate potential financial risks.
Income Statement
45
Neutral
Mabpharm Limited has shown significant revenue growth of 196.24% from the previous year, indicating strong top-line expansion. However, the company remains unprofitable with a negative net profit margin of -49.55% and a negative EBIT margin of -46.34%. Despite the improvement in revenue, consistent losses over the years indicate challenges in achieving profitability.
Balance Sheet
35
Negative
The company exhibits a high debt-to-equity ratio of 3.50, reflecting substantial leverage and potential financial risk. The return on equity is negative at -143.89%, aligning with ongoing net losses. The equity ratio of 8.75% suggests limited equity as a proportion of total assets, further emphasizing financial instability.
Cash Flow
30
Negative
Mabpharm Limited's cash flow statements reveal challenges with cash generation, as evidenced by the absence of free cash flow and operating cash flow for the current period. Historical free cash flow has been negative, indicating ongoing cash management issues. The inability to generate positive operating cash flow relative to net income further highlights the need for operational improvements.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue258.23M87.16M55.92M82.88M0.00
Gross Profit219.39M75.24M40.54M66.11M0.00
EBITDA-67.81M-139.08M-152.08M-245.46M-169.93M
Net Income-127.95M-209.36M-210.62M-294.22M-188.57M
Balance Sheet
Total Assets1.02B1.03B917.52M899.90M1.16B
Cash, Cash Equivalents and Short-Term Investments89.34M173.34M48.61M81.56M484.85M
Total Debt293.09M260.07M126.34M45.69M40.35M
Total Liabilities927.28M829.92M516.58M297.92M281.55M
Stockholders Equity88.93M205.06M400.94M601.98M881.49M
Cash Flow
Free Cash Flow-63.58M38.35M-182.01M-348.14M-344.47M
Operating Cash Flow-4.10M57.39M-56.88M-199.47M-147.23M
Investing Cash Flow-98.20M-3.50M-104.95M-179.42M156.00M
Financing Cash Flow18.28M85.60M112.26M-17.78M-80.48M

Mabpharm Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.52
Price Trends
50DMA
0.50
Positive
100DMA
0.49
Positive
200DMA
0.41
Positive
Market Momentum
MACD
0.02
Negative
RSI
58.70
Neutral
STOCH
42.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2181, the sentiment is Positive. The current price of 0.52 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.50, and above the 200-day MA of 0.41, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.70 is Neutral, neither overbought nor oversold. The STOCH value of 42.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2181.

Mabpharm Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$1.92B48.164.92%38.48%
60
Neutral
HK$17.54B4.97-4.95%3.61%9.71%-38.85%
57
Neutral
HK$3.49B-31.66%30.54%48.43%
52
Neutral
HK$4.01B-75.64%42.21%29.52%
48
Neutral
HK$2.19B-86.56%190.48%40.11%
37
Underperform
HK$2.16B-228.99%44.88%
32
Underperform
HK$1.74B-12.49%50.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2181
Mabpharm Limited
0.52
0.16
44.44%
HK:6978
Immunotech Biopharm Ltd
4.08
1.13
38.31%
HK:3681
SinoMab Bioscience Ltd.
3.36
1.77
111.32%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.04
2.59
178.62%
HK:1875
TOT BIOPHARM International Co. Ltd.
2.49
0.54
27.69%
HK:6996
Antengene Corporation Limited
5.50
4.91
832.20%

Mabpharm Limited Corporate Events

Mabpharm Limited Announces Unanimous Approval of AGM Resolutions
Jun 18, 2025

Mabpharm Limited announced that all proposed resolutions at its Annual General Meeting held on June 18, 2025, were passed unanimously by shareholders. These resolutions included the re-election of directors, the re-appointment of auditors, and the granting of mandates to the board for share repurchase and issuance. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational stability.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025